Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Significant Growth in Short Interest

Tiziana Life Sciences Ltd (NASDAQ:TLSA) was the recipient of a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 1,220,000 shares, a growth of 128.0% from the January 15th total of 535,000 shares. Based on an average trading volume of 595,600 shares, the days-to-cover ratio is presently 2.0 days. Currently, 1.7% of the shares of the stock are sold short.

Tiziana Life Sciences Price Performance

NASDAQ TLSA traded down $0.00 on Thursday, hitting $0.75. The company had a trading volume of 254,185 shares, compared to its average volume of 899,317. Tiziana Life Sciences has a 12-month low of $0.41 and a 12-month high of $1.74. The company’s fifty day moving average price is $0.78 and its 200-day moving average price is $0.93.

Institutional Trading of Tiziana Life Sciences

Institutional investors and hedge funds have recently modified their holdings of the stock. Zhang Financial LLC lifted its stake in Tiziana Life Sciences by 24.2% in the 3rd quarter. Zhang Financial LLC now owns 69,387 shares of the company’s stock valued at $67,000 after buying an additional 13,500 shares in the last quarter. Sanctuary Advisors LLC acquired a new stake in shares of Tiziana Life Sciences in the third quarter worth approximately $864,000. Finally, Geode Capital Management LLC boosted its stake in shares of Tiziana Life Sciences by 12.4% in the fourth quarter. Geode Capital Management LLC now owns 245,722 shares of the company’s stock worth $171,000 after acquiring an additional 27,041 shares during the last quarter.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.